<DOC>
	<DOCNO>NCT00116571</DOCNO>
	<brief_summary>The purpose study determine transurethral photodynamic therapy lemuteporfin therapeutic effect lower urinary tract symptom due enlarge prostate . Photodynamic therapy ( know `` PDT '' ) treatment use light make drug work . This mean drug `` light-activated '' . Light-activated drug work certain color light shine drug . When drug light combine , react together destroy tissue . This study investigate PDT lemuteporfin possible treatment enlarge prostate . PDT lemuteporfin may destroy overgrown prostate tissue help urinary symptom go back normal .</brief_summary>
	<brief_title>Photodynamic Therapy ( PDT ) Lower Urinary Tract Symptoms ( PLUS )</brief_title>
	<detailed_description>This multi-center , randomize , sham-controlled , double-blind , dose-finding study parallel group subject low urinary tract symptom ( LUTS ) due benign prostatic hyperplasia ( BPH ) . All subject receive fix dose lemuteporfin inject transurethrally prostate follow transurethral application either one three active light dos sham light dose . Subjects follow safety efficacy minimum three month maximum 12 month . The primary study endpoint change baseline AUA SI score three month .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<criteria>Men 21 year age old . Subjects LUTS due BPH AUA SI score 13 Qmax 5 15 mL/sec . Subjects urethral treatment length least 25 mm . Subjects previous minimally invasive surgical treatment BPH . Subjects unsuitable prostate dimension .</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>Benign Prostatic Hyperplasia ( BPH )</keyword>
	<keyword>Photodynamic Therapy ( PDT )</keyword>
	<keyword>Lower Urinary Tract Symptoms ( LUTS )</keyword>
</DOC>